Navigation Links
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Date:5/21/2008

ential for a significant improvement in skin-related side effects," Dr. Staskin said.

"Watson Urology is making a broader, more visible commitment to the medical and patient communities," said Heimers. "Through our innovative pipeline, we are focused on developing effective, safe and convenient treatments that not only treat the symptoms of common urological conditions but also offer patients quality of life advantages."

The two trials presented at AUA are part of Watson's comprehensive R&D program, and represent the company's focus on providing products and services that improve the quality of patients' lives. In addition, Watson recently announced the approval of MIXJECT(R), a new delivery system for TRELSTAR(R) DEPOT 3.75 mg and TRELSTAR(R) LA 11.25 mg (triptorelin pamoate for injectable suspension), a palliative treatment for advanced prostate cancer. MIXJECT(R) combines the proven efficacy of TRELSTAR(R) with new features that make preparation, administration and disposal easier, including: a thinner 21-gauge needle for improved patient comfort; reconstitution without the use of a needle; and a shield covering the needle both before and after drug administration. The system, developed and manufactured by West Pharmaceutical Services, Inc., is specifically designed to encourage compliance with OSHA (Occupational Safety and Health Administration) regulations within the medical community.

About Silodosin

Silodosin is a novel, highly uroselective alpha (1A)-adrenoceptor antagonist originally developed by Kissei Pharmaceutical Co., Ltd. in Japan and licensed to Watson for the US, Canada and Mexico markets. Silodosin preferentially binds to the alpha (1A) receptors in the prostate and bladder neck relative to cardiovascular associated receptors, thereby maximizing target organ activity while minimizing the potential for blood pressure effects. Urief(R) (silodosin) 4mg, dosed twice daily, was launched in Japan in May 2006 and is marketed by
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Launches Generic Biaxin(R) XL
4. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
5. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
6. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
7. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
8. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
9. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
10. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)..., Nov. 25 Poniard,Pharm...tical company focused on,innovative oncology ther...strategic alternatives for its preclinical researc... its resources on the clinical development of pico...t the initial commercialization of,picoplatin in ...
(Date:11/25/2008)...ire-FirstCall/ -- CardioVascular,BioTherapeutics,...that it has,dosed the first patient in North Amer...rial to treat patients with severe coronary heart ...t of CORonary heart Disease) trial will include,f...oses in approximately 120,patients with severe co...
(Date:11/24/2008)...PRNewswire-FirstCall/ -- Leaders of Schering-Ploug...ate for investors on the company,s research pipeli...hat includes 46 new entities in clinical trials or...dies. , , "Research and development is addi...ontinue our transformation," said Fred Hassan, cha...
(Date:11/24/2008)...day Unveils Rich Development Pipeline of Compounds...ORTH, N.J., Nov. 24 Sche...led top-line results of a long-term Phase III clin...S(TM) (asenapine) demonstrating efficacy and safet... trial, asenapine was statistically significantly ...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 2Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 3Hear Indiana Announces Talk Walk Run 2008 18272 1Hear Indiana Announces Talk Walk Run 2008 18272 2Hear Indiana Announces Talk Walk Run 2008 18272 3Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 1Pennsylvania Pharmacy Carve out Poses Risks for Commonwealths Neediest Citizens and Taxpayers National Organization Testifies 18270 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 1Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 2Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees 5072 3GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 1GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 2GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 5070 3
... /PRNewswire/ -- Results of the,Option (TOcilizuma...ers) trial, the first multinational Phase III stud...ith Actemra (either 4mg/kg,or 8mg/kg) plus methotr...ant improvement in the signs and symptoms of moder...o patients treated with,placebo and methotrexate, ...
...Biotech (OMX Nordic: ACTI) presented,pre-clinical ...The,European League Against Rheumatism, <a target=...rg ) conference, June,13-16*. , "The new pre-clin...nt inhibitory effect on disease development in an,... commented Sven,Andréasson, President &...
Other Medicine Technology:Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5New Positive Pre-clinical Data for Active Biotech's RA Project I-3D 2
(Date:12/2/2008)... Orion Health announces that the Sou...of Juneau, Alaska, has selected the Rhapsody&trade...nic health record, radiology, pharmacy, laboratory.... It also plans to extend connectivity to statewid...unization registry) and AKAIMS (an MIS and clinica...
(Date:12/2/2008)... Dec. 2 Population Serv...hensive project that could dramatically reduce the...malaria. The program will provide free artemisinin...community health workers to poor children suspecte...to treatment will be monitored to determine if it ...
(Date:12/1/2008)...es ,Asthma & Allergy Friendly, Toy Puppies to ... Much has been made of P...ily dog. But concerns about his daughter,s asthma...ew first-dad from making a decision. So, in the m...ica (AAFA) is donating 2 "asthma & allergy fri...
(Date:12/1/2008)...New research reveals that computed tomography (CT)...has the potential to screen for two diseases at on...h commonly affect adults over age 50. Results of t...ting of the Radiological Society of North America ...screening for colorectal cancer, we were able to i...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...id could provide ample energy if used properly is ...rican Journal of Physiology - Endocrinology and Me...d colleagues Takeshi Hashimoto and Rajaa Hussien i...ratory add one of the last puzzle pieces to the la...
... to a report published in Geneva it was found that...research work on diseases such as AIDS and malaria... many developing countries, especially in sub-Saha...y the Global Forum for Health Research. Stephen Ma...
...cefully can sometimes be a problem especially when... facilities looms large. //Marilyn Rantz, nursing ... calls this as a slippery slope and says that ther...m getting onto this slope. Consumers say they nev...
...more number of bus drivers and conductors in India...is that of the bus conductor Ravindra Kamble (34).... conductors in the last one year have been tested ...programme was started by General Manager SS Kshatr...
Other Medicine News:Health News:Lactic acid a potent energy giver if used properly! 2
Inquiry H Steerable Catheter. Steerable atrial mapping catheter offers a variety of designs and a unique 45 offset for catheter stability. 10 to 24 electrodes, regular and large steerable curves, ina
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures.
...or a complete line of deflectable coronary sinus (...all with the quality, reliability and precise perf...atheter technology. All of our deflectable coronar...gned and constructed to help minimize the frustrat...
Inquiry 5FR Soft HIS diagnostic catheters provide the electrophysiologist with a uniquely designed curve that allows for placement and recording in the HIS bundle. In addition, the soft tubing is des
Medicine Products: